more

Collegium Pharmaceutical (COLL)

(Delayed Data from NSDQ)

$36.71 USD

+0.29 (0.80%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $36.73 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

Top 36% (91 out of 252)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer

by Zacks Equity Research Published on March 30,2022

ImmunoGen (IMGN) seeks accelerated approval from the FDA for its lead candidate, mirvetuximab soravtansine, in previously treated platinum-resistant ovarian cancer. This pushes the stock price up.

medical

Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development

by Zacks Equity Research Published on March 29,2022

Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.

biotechs

Novo Nordisk (NVO) Gets FDA Nod for Ozempic's Label Expansion

by Zacks Equity Research Published on March 29,2022

The FDA approves Novo Nordisk's (NVO) Ozempic 2.0 mg dose for the treatment of adults with type II diabetes. The medicine is now approved at 0.5 mg, 1.0 mg and 2.0 mg doses for the given indication.

pharmaceuticals

Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug

by Zacks Equity Research Published on March 25,2022

Mei Pharma's (MEIP) FDA filing plans for zandelisib for lymphoma indication get derailed after the agency requests more clinical studies. The stock plummets in after-market trading post this news.

medical

Lilly (LLY) Gets CRL from FDA for Sintilimab in Lung Cancer

by Zacks Equity Research Published on March 25,2022

Lilly (LLY) gets a complete response letter from the FDA for the biologics license application for sintilimab plus pemetrexed and platinum chemotherapy for treating first-line lung cancer.

pharmaceuticals

JAZZ Initiates Zepzelca Basket Study in Advanced Solid Tumors

by Zacks Equity Research Published on March 25,2022

JAZZ enrolls the first patient in a mid-stage study to evaluate its lung cancer drug, Zepzelca, in advanced and difficult-to-treat cancer indications in previously-treated patients.

pharmaceuticals

Novartis' (NVS) Pluvicto Gets FDA Nod for Advanced Prostate Cancer

by Zacks Equity Research Published on March 24,2022

The FDA okays Novartis' (NVS) targeted radioligand therapy Pluvicto to treat PSMA-positive metastatic castration-resistant prostate cancer.

pharmaceuticals

COLL or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on March 21,2022

COLL vs. ZTS: Which Stock Is the Better Value Option?

Has Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on March 17,2022

Here is how Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.

Are Investors Undervaluing These Medical Stocks Right Now?

by Zacks Equity Research Published on March 15,2022

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Sanofi's (SNY) Breast Cancer Candidate Misses Goal in Study

by Zacks Equity Research Published on March 14,2022

Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.

pharmaceuticals

Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B

by Zacks Equity Research Published on March 11,2022

Bayer (BAYRY) to sell off its Environmental Science Professional business unit to Cinven for $2.6 billion. The company plans to focus on core agricultural businesses.

pharmaceuticals

Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why

by Zacks Equity Research Published on March 10,2022

Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.

medical

Bayer (BAYRY) Files for Nubeqa's Label Expansion in US & EU

by Zacks Equity Research Published on March 10,2022

Bayer (BAYRY) submits regulatory applications to the FDA and the EMA, seeking approval for a new indication of Nubeqa for treating metastatic hormone-sensitive prostate cancer.

pharmaceuticals

COLL or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on March 03,2022

COLL vs. ZTS: Which Stock Is the Better Value Option?

New Strong Buy Stocks for March 3rd

by Zacks Equity Research Published on March 03,2022

ACGL, ACLS, COLL, SAH, and TGH have been added to the Zacks Rank #1 (Strong Buy) List on March 3, 2022.

Biohaven's (BHVN) Q4 Earnings Miss, Nurtec Gets CHMP Nod

by Zacks Equity Research Published on February 28,2022

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The CHMP recommends approval of Nurtec ODT. Stock declines.

Can Collegium Pharmaceutical (COLL) Climb 30% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research Published on February 28,2022

The average of price targets set by Wall Street analysts indicates a potential upside of 29.9% in Collegium Pharmaceutical (COLL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

COLLPositive Net Change

Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut

by Zacks Equity Research Published on February 25,2022

Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.

United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down

by Zacks Equity Research Published on February 25,2022

United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.